The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma...
The oral proteasome inhibitor ixazomib (Ninlaro®) is approved in the USA, EU and Japan in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy.
Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Takeda announced that a New Drug Application (NDA) has been submitted to the FDA for ixazomib, an investigational oral proteasome...
Areas covered: In this review, we provide an overview of the preclinical and early-phase studies of ixazomib used as single-agent and in combination. Furthermore, we discuss the results of a recently published pivotal trial...
The National Institute for Health and Care Excellence (NICE), in a draft recommendation, has rejected Ninlaro (ixazomib) combination with lenalidomide...
Takeda Pharmaceutical Company Limited announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of Ninlaro (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients.
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Certain cytogenetic abnormalities are known to adversely impact outcomes in patients with multiple myeloma (MM). The phase 3 TOURMALINE-MM1 study demonstrated a significant improvement in progression-free survival (PFS)...
Takeda Pharmaceutical has announced that the European Commission has granted conditional marketing authorization for Ninlaro (ixazomib) capsules, indicated in combination...